DOI:
10.1055/s-00000097
Deutsche Zeitschrift für Onkologie
LinksClose Window
References
Miles DW, Gligorov J, André F. et al.
Primary results from IMpassion131, a double-blind placebo-controlled randomised
phase III trial of first-line paclitaxel (PAC)±atezolizumab (atezo) for
unresectable locally advanced/metastatic triple-negative breast cancer
(mTNBC).
Ann Oncol 2020;
31: S1142-S1215
Search in:
Access:
We do not assume any responsibility for the contents of the web pages of other providers.